Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases

PURPOSE: The combination of the oral alkylating agent temozolomide and the oral multi-kinase inhibitor sorafenib was evaluated in advanced melanoma patients. PATIENTS AND METHODS: Patients with metastatic melanoma (N=167) were treated on four arms. All patients received sorafenib at 400 mg orally tw...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Amaravadi, Ravi K., Schuchter, Lynn M., McDermott, David F., Kramer, Amy, Giles, Lydia, Gramlich, Kristi, Carberry, Mary, Troxel, Andrea B., Letrero, Richard, Nathanson, Katherine L., Atkins, Michael B., O’Dwyer, Peter J., Flaherty, Keith T.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2795076/
https://ncbi.nlm.nih.gov/pubmed/19996224
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-2074
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados